Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-07-10 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". Form 8.3 is a mandatory disclosure required under the UK Takeover Code when a person holding interests in relevant securities representing 1% or more makes a dealing during an offer period. This form details the person's position and any dealings undertaken. This specific disclosure relates to insider/major shareholder activity during a potential takeover scenario, which aligns most closely with Director's Dealing (DIRS) or a specific type of regulatory filing related to transactions. Since DIRS is defined as 'Report of personal share transactions by company directors and executives (insider trades)', and this is a mandatory disclosure of a major shareholder's position and dealings during a takeover context, it falls under the scope of insider/significant transaction reporting. Given the options, 'DIRS' (Director's Dealing) is the closest fit for mandatory disclosure of significant share transactions/positions by an interested party, although it is broader than just directors. If a more specific 'Takeover Disclosure' category existed, it would be preferred, but among the provided codes, DIRS captures the essence of reporting significant security interests and transactions by insiders/major holders.
2023-07-10 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is clearly identified as a 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. This form is used to report changes in significant share ownership, which falls under regulatory disclosure requirements for major shareholders. The presence of 'RNS Number' and the structure strongly suggest a regulatory filing related to shareholding changes, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although it is an RNS announcement, MRQ is more specific than the general RNS fallback.
2023-07-10 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is used by parties involved in a takeover bid to disclose their interests and dealings in the relevant securities. This type of disclosure, related to insider/significant shareholder activity during a takeover scenario, is best classified under Director's Dealing (DIRS) or potentially Regulatory Filings (RNS). However, given the specific nature of reporting personal/firm dealings related to a takeover bid, it aligns most closely with the spirit of insider transaction reporting, which is covered by DIRS, although DIRS usually refers to director's dealings, this is a broader disclosure required during a takeover. Since there is no specific code for 'Takeover Disclosure', and it involves reporting dealings by a significant holder (Millennium International Management LP) in relation to an offer for Dechra Pharmaceuticals plc, it falls under the category of significant transaction/insider reporting. Comparing the definitions, 'Director's Dealing (DIRS)' is the closest fit for reporting personal share transactions by executives/insiders, which this disclosure functionally represents in the context of a takeover. If DIRS is strictly for directors, then RNS (Regulatory Filings) would be the fallback. Given the context of 'dealing disclosure' by a major holder during a potential takeover, DIRS is often used broadly for significant insider/stakeholder transaction reporting in some classification schemes, but RNS is the safest fallback for specific regulatory forms not explicitly listed. Let's re-evaluate: Form 8.3 is a mandatory disclosure under the UK Takeover Code. It is a regulatory filing. Since 'Director's Dealing (DIRS)' is defined as 'Report of personal share transactions by company directors and executives (insider trades)', and this is a report by an investment manager (Millennium) regarding a takeover, it is a specific regulatory filing that doesn't perfectly match DIRS. Therefore, the most appropriate general category for a specific, non-standard regulatory form is 'Regulatory Filings' (RNS).
2023-07-07 English
Form 8.3 - Dechra Pharmaceuticals PLC
Regulatory Filings Classification · 95% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code". This form is used to disclose interests and dealings in securities during a takeover offer period. This specific type of regulatory disclosure, related to insider/major shareholder activity during a takeover, does not fit neatly into the provided standard categories like 10-K, ER, or IR. Since it is a specific regulatory filing related to corporate actions (takeover), and 'RNS' is defined as the fallback for miscellaneous regulatory filings, RNS is the most appropriate classification among the choices, although 'LTR' (Legal Proceedings Report) or 'MRQ' (Major Shareholding Notification) might seem tangentially related, Form 8.3 is a distinct disclosure required by the Takeover Code, best captured by the general regulatory filing category.
2023-07-07 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 2677F" and contains the standard boilerplate text indicating it is provided by RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. The content details a "TR-1: Standard form for notification of major holdings" concerning an acquisition or disposal of voting rights by Societe Generale, crossing a threshold on 05-Jul-2023. This type of mandatory disclosure regarding changes in significant share ownership thresholds directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-07-07 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is used to disclose interests and dealings in securities related to a takeover offer. This type of disclosure, concerning insider/significant shareholder activity during a takeover scenario, is a specific type of regulatory filing related to insider trading or ownership changes during M&A activity. While it relates to M&A (TAR), the specific nature of this disclosure (Form 8.3 under the Takeover Code) is best categorized as a specialized regulatory filing concerning director/insider dealings or major shareholding changes in the context of a bid. Given the options, 'Director's Dealing' (DIRS) covers personal transactions by executives, and 'Major Shareholding Notification' (MRQ) covers crossing ownership thresholds. Since this is a mandatory disclosure by a significant holder (Millennium International Management LP) regarding their position during an offer for Dechra Pharmaceuticals plc, it strongly aligns with reporting insider/significant ownership changes related to corporate control events. However, Form 8.3 is a specific disclosure required by the Takeover Code, which is a regulatory requirement. Since it details the position and dealings of a person with interests in relevant securities (often an insider or major shareholder), it fits best under the umbrella of insider/director dealings or major shareholding notifications. Given the context of a takeover bid (implied by the Takeover Code reference), it is a specific type of insider disclosure. 'DIRS' (Director's Dealing) is the closest fit for reporting personal share transactions/interests by key parties, even if the discloser isn't strictly a director, as it captures insider/significant stakeholder activity reporting. If 'DIRS' is too narrow, 'MRQ' (Major Shareholding Notification) is also plausible, but Form 8.3 is more specific to takeover situations. Since the document details the position and dealings of a significant entity (Millennium International Management LP) in relation to an offer, and it is a mandatory regulatory filing, I will classify it as a specific type of insider/major shareholder disclosure. Given the options, 'DIRS' captures the essence of reporting personal/controlled interests and dealings, which is the core function here, even if the discloser is an investment manager rather than a director. Alternatively, 'MRQ' covers changes in significant share ownership. Since the document explicitly details ownership percentages (1.235%) and dealings, 'MRQ' is a strong candidate. However, Form 8.3 is a specific takeover-related disclosure. In the absence of a specific 'Takeover Disclosure' code, 'DIRS' (Director's Dealing) is often used broadly for insider transaction reporting, or 'MRQ' for significant ownership changes. Given the context of a takeover, this is a mandatory disclosure of a significant position. I will lean towards 'DIRS' as it covers the reporting of interests/dealings by influential parties, which is the primary content.
2023-07-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.